Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adicet Bio Inc (NQ: ACET )

10.44 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 10.44
Bid (Size) 9.440 (2)
Ask (Size) 10.54 (1)
Prev. Close 10.44
Today's Range 10.44 - 10.44
52wk Range 6.250 - 21.17
Shares Outstanding 40,004,357
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire

Performance

YTD
-43.04%
-43.04%
1 Month
-34.34%
-34.34%
3 Month
-28.79%
-28.79%
6 Month
+11.18%
+11.18%
1 Year
-23.96%
-23.96%

More News

Read More
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Where Adicet Bio Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Via Benzinga
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 4, 2022
Via Benzinga
Adicet Bio to Participate in Guggenheim 2022 Oncology Conference
From Adicet Bio, Inc.
Via Business Wire
4 Stocks Insiders Are Buying
Via Benzinga
Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate
Via Benzinga
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
60 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 700 Points; Del Taco Restaurants Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 3%; Aeglea BioTherapeutics Shares Plunge
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
36 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Adicet Bio Stock Is Skyrocketing Today
Via The Motley Fool
Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's Lymphoma
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.